483 results on '"O'Shaughnessy, Michael V."'
Search Results
2. The Incidence and Spectrum of AIDS-Defining Illnesses in Persons Treated with Antiretroviral Drugs
3. Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Triple-Drug Antiretroviral Therapy
4. Prevalence and Correlates of Untreated Human Immunodeficiency Virus Type 1 Infection among Persons Who Have Died in the Era of Modern Antiretroviral Therapy
5. Requiring Help Injecting as a Risk Factor for HIV Infection in the Vancouver Epidemic: Implications for HIV Prevention
6. Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease
7. Rates of Disease Progression among Human Immunodeficiency Virus-Infected Persons Initiating Multiple-Drug Rescue Therapy
8. Mitochondrial: Nuclear DNA Ratios in Peripheral Blood Cells from Human Immunodeficiency Virus (HIV)-infected Patients Who Received Selected HIV Antiretroviral Drug Regimens
9. Health and Socioeconomic Status Differences Among Antibody Hepatitis C Positive and Negative Transfusion Recipients, 1986-1990
10. Modern Antiretroviral Therapy Improves Life Expectancy of Gay and Bisexual Males in Vancouver's West End
11. Evidence for a Sexually Transmitted Cofactor for AIDS-Related Kaposi's Sarcoma in a Cohort of Homosexual Men
12. Deadly Public Policy: What the Future Could Hold for the HIV Epidemic among Injection Drug Users in Vancouver
13. Do Dual Nucleoside Regimens Have a Role in an Era of Plasma Viral Load-Driven Antiretroviral Therapy?
14. Stavudine Plus Lamivudine in Advanced Human Immunodeficiency Virus Disease: A Short-Term Pilot Study
15. Serum Levels of Human Immunodeficiency Virus Type 1 (HIV-1) RNA after Seroconversion: A Predictor of Long-Term Mortality in HIV Infection
16. A Pilot Study of Hydroxyurea among Patients with Advanced Human Immunodeficiency Virus (HIV) Disease Receiving Chronic Didanosine Therapy: Canadian HIV Trials Network Protocol 080
17. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy
18. An external evaluation of a peer-run “Unsanctioned” syringe exchange program
19. Predictors of early hospital readmission in HIV-infected patients with pneumonia
20. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA
21. The impact of adherence on CD4 cell count responses among HIV-infected patients
22. HIV-positive injection drug users who leave the hospital against medical advice
23. Mitochondrial toxicity in the era of HAART: Evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy
24. Sexual violence among a cohort of injection drug users
25. Impaired virologic response to highly active antiretroviral therapy associated with ongoin injection drug use
26. The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users
27. The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS
28. Factors Associated with Willingness to Participate in HIV Vaccine Trials Among HIV-Negative Injection Drug Users and Young Gay and Bisexual Men
29. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy
30. Satellite needle distribution among injection drug users: policy and practice in two Canadian cities
31. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort
32. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs
33. 'Discordant' increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy
34. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients
35. The social determinants of emergency department and hospital use by injection drug users in Canada
36. “A Lot of Things I Hide”: Understanding Disclosure in the Care of HIV-Positive Bisexual Men
37. Purification of RBF-2, a transcription factor with specificity for the most conservedcis-element of naturally occurring HIV-1 LTRs
38. Impact of HIV infection on mortality in a cohort of injection drug users
39. Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug Therapy. (Original Contribution)
40. The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?
41. Depressive symptoms decline among persons on HIV protease inhibitors
42. “They Don't See Our Feelings.” The Health Care Experiences of HIV-Positive Transgendered Persons
43. Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy
44. Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV—Positive Adult Men and Women
45. One year after MedImmune - the impact on patent licensing & negotiation.
46. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
47. Primary Lamivudine Resistance in Acute/Early Human Immunodeficiency Virus Infection
48. Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health
49. A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects
50. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.